GFM
NTLA icon

GF Fund Management’s Intellia Therapeutics NTLA Stock Holding History

GF Fund Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$42.3K Sell
2,502
-85
-3% -$1.19K ﹤0.01% 405
2026
Q1 		$33.2K Buy
2,587
+312
+14% +$3.97K ﹤0.01% 449
2025
Q4 		$20.5K Sell
2,275
-35
-2% -$482 ﹤0.01% 508
2025
Q3 		$39.9K Sell
2,310
-298
-11% -$3.67K ﹤0.01% 418
2025
Q2 		$24.5K Hold
2,608
– – ﹤0.01% 481
2025
Q1 		$18.5K Buy
2,608
+469
+22% +$4.74K ﹤0.01% 510
2024
Q4 		$24.9K Buy
+2,139
New +$33.4K ﹤0.01% 453

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

GF Fund Management's NTLA Position: Q2 2026 in Review

GF Fund Management reduced its Intellia Therapeutics (NTLA) stake by 3.3% in Q2 2026, selling an estimated $1.19K and leaving 2,502 shares worth $42.3K. The position accounts for ﹤0.01% of the portfolio, ranked #405.

GF Fund Management first reported a position in NTLA in Q4 2024 and has held it in 7 quarters since. 329 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • GF Fund Management held 2,502 shares of Intellia Therapeutics worth $42.3K as of Q2 2026.
  • GF Fund Management sold 85 Intellia Therapeutics shares in Q2 2026, an estimated $1.19K.
  • Intellia Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #405 holding.
  • GF Fund Management first reported a position in Intellia Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 329 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.